Air-sham

OTHER2 trials

Sponsors

Airway Therapeutics, Inc.

Conditions

Bronchopulmonary Dysplasia

Phase 1

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

CompletedNCT04662151

Airway Therapeutics, Inc.Bronchopulmonary Dysplasia

Start: 2021-09-01End: 2024-05-29Updated: 2024-07-03

Phase 2

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

RecruitingNCT06897839

Airway Therapeutics, Inc.Bronchopulmonary Dysplasia

Start: 2025-02-03End: 2030-04-30Target: 366Updated: 2026-02-06

Related Papers

A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia

Frontiers in Pediatrics2025-09-12